Haleon plc

$11
(as of Jun 6, 9:30 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Haleon plc

Stock Price
$11
Ticker Symbol
HLN
Exchange
NYSE

Industry Information for Haleon plc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Haleon plc

Country
USA
Full Time Employees
24,561

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Fundamentals for Haleon plc

Market Capitalization
$51,348,992,000
EBITDA
$2,683,000,064
Dividends per Share
$0.07
P/E Ratio
27.17
Forward P/E Ratio
22.32
Earnings per Share
$0.42
Earnings per Share Estimate Next Year
Profit Margin
12.84%
Shares Outstanding
4,500,349,952
Percent Owned by Insiders
0.02%
Percent Owned by Institutions
12.71%
52-Week High
52-Week Low

Technical Indicators for Haleon plc

50-Day Moving Average
200-Day Moving Average
RSI
57.98
0.19

Analyst Ratings for Haleon plc

Strong Buy
2
Buy
1
Hold
1
Sell
0
Strong Sell
0

News About Haleon plc

May 8, 2025, 2:00 AM EST
Most readers would already be aware that Haleon's (LON:HLN) stock increased significantly by 13% over the past month. See more.
May 1, 2025, 8:00 AM EST
Forager® AI Platform to Enable Haleon’s Scientists to Unlock the Power of Nature for Consumer Health See more.
Apr 25, 2025, 1:00 AM EST
Earnings season is now in full swing, with a number of key companies due to report in the coming week, including four of the Magnificent 7 tech giants in focus. See more.
Mar 21, 2025, 12:26 PM EST
This week, the FDA approved J&J’s JNJ Tremfya for its second inflammatory bowel disease (“IBD”) condition, Crohn’s disease (“CD”), and Novartis’ NVS Fabhalta for its third indication, C3 glomerulopathy (C3G). See more.